ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 25, 2017--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that the Data Safety Monitoring Board (DSMB)
has authorized the Company to move forward with enrollment for cohort 3.
The DSMB is an independent group of medical experts closely monitoring
the Phase I/IIa OpRegen® clinical trial. In cohort 3 BioTime plans to
treat patients at its current sites in Israel and at two US sites, with
leading ophthalmologists: Dr. David S. Boyer, Retina-Vitreous Associates
Medical Group and Dr. H. Richard McDonald, West Coast Retina Medical
The administration of the implant in cohort 3 is being optimized for
cell concentration and volume prior to Cohort 4. In cohort 4, the
Company plans to treat patients in earlier stages of the disease that
are likely be the target patient population for the therapy.
“Our team is enthusiastic about the early data showing a positive
response from the implanted cells,” commented Dr. McDonald. “The DSMB’s
approval is an important milestone. We look forward to enrolling our
first patient in the trial as this is a debilitating disease."
“We are seeing encouraging signals of biological activity in the early
stages of the OpRegen clinical program and we look forward to the
continued progression of the trial,” commented Adi Mohanty, co-Chief
Executive Officer. “We will start enrolling patients in cohort 3 in the
coming weeks in both Israel and the U.S. Our goal is to complete this
cohort during the fourth quarter of 2017.”
The Phase I/IIa clinical trial is evaluating the safety and efficacy of
implantation regimens of OpRegen in the advanced form of dry-AMD.
Dry-AMD is the leading cause of blindness in people over 60, and a
condition for which there is currently no FDA-approved therapy.
OpRegen has received Fast Track designation from the U.S. Food and Drug
Administration (FDA) for the treatment of dry-AMD, which comprises
approximately 90% of those afflicted with AMD.
The Company presented data from the Phase I/IIa clinical trial
of OpRegen at the Association for Research in Vision and Ophthalmology
(ARVO) annual meeting in May. The presentation reported clinical trial
data from patients in the first two cohorts. Imaging analysis suggests
the transplanted OpRegen cells remained in place (engrafted) even at the
one year follow up and particularly uniquely in an area of the scar that
was completely depleted of retinal pigment epithelium (RPE) because of
the advanced stages of the disease. There was also possible evidence of
a biological response with some areas appearing to show structural
improvement (a thickening of the area of the neural retina above the
scar) without any signs of retinal edema, a fluid build-up that can
further compromise vision.
OpRegen®, which is being studied for the treatment of the dry
form of age-related macular degeneration (AMD), consists of a suspension
of Retinal Pigment Epithelial (RPE) cells that are delivered
subretinally during a simple intraocular injection. RPE cells are
essential components of the back lining of the retina, and function to
help nourish the retina including photoreceptors. A proprietary process
that drives the differentiation of human pluripotent stem cells is used
to generate high purity OpRegen® RPE cells. OpRegen® RPE
cells are also “xeno-free," meaning that no animal products are used at
any point in the derivation and production process. The avoidance of the
use of animal products eliminates some potential safety concerns.
Preclinical studies in rats have shown that following a single
subretinal injection of OpRegen®, the cells can rapidly organize into
its natural monolayer structure in the subretinal space and survive
throughout the lifetime of the animal. OpRegen® is designed
to be an “off-the-shelf” allogeneic (non-patient specific) product.
Unlike treatments that require multiple, frequent injections into the
eye, it is expected that OpRegen® would be administered in a
single procedure. OpRegen® was granted Fast Track designation from FDA,
which allows more frequent interactions with the agency, and eligibility
for accelerated approval and priority review. OpRegen® is a registered
trademark of Cell Cure Neurosciences Ltd., a majority-owned subsidiary
of BioTime, Inc.
About Dry Age-Related Macular Degeneration (Dry-AMD)
Macular degeneration affects approximately 11 million people in the U.S.
and is the leading cause of blindness in people over the age of 60.
Approximately 90 percent of these patients suffer from the dry form, for
which there are no FDA-approved therapies. In dry-AMD, there is a loss
or dysfunction of the layer of retinal pigment epithelial (RPE) cells
generally in the region of the eye called the macula, which is the part
of the retina responsible for sharp, central vision that is important
for facial recognition, reading and driving. These RPE cells support the
light detecting photoreceptor cells that are so critical to vision. When
we look at something, the photoreceptors (rods and cones) detect the
light and send the information to the brain allowing us to perceive our
surroundings. The age-dependent loss of the RPE cells therefore leads to
degeneration of nearby photoreceptors and this can lead to severe vision
loss or even legal blindness. Generally, the damage caused by the “dry”
form is not as severe or rapid as that of the “wet” form. However, in
the advanced stage of dry macular degeneration widespread loss of RPE
and photoreceptors in the macular area, called geographic atrophy, leads
to severe vision loss. While therapeutics are available to treat the wet
form of AMD, there are currently no FDA-approved therapies for dry-AMD.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products. BioTime also
has significant equity holdings in two publicly traded companies,
Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which BioTime
founded and which, until recently, were majority-owned consolidated
subsidiaries of BioTime.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for BioTime, Inc. and its
subsidiaries, along with other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the business of BioTime, Inc. and its
subsidiaries, particularly those mentioned in the cautionary statements
found in more detail in the “Risk Factors” section of its Annual Reports
on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC
(copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. BioTime specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170725006509/en/
Source: BioTime, Inc.
EVC Group, Inc.
JQA Partners, Inc.
Jules Abraham, 917-885-7378